Valuation: Royalty Pharma plc

Market Cap 25.6B 22.21B 20.8B 19.03B 35.92B 2,439B 36.39B 243B 95.51B 1,218B 96.11B 94.03B 4,055B P/E 2026 *
18.9x
P/E 2027 * 16.6x
Enterprise Value 34.69B 30.1B 28.19B 25.78B 48.68B 3,304B 49.31B 330B 129B 1,651B 130B 127B 5,495B EV / Sales 2026 *
9.99x
EV / Sales 2027 * 9.29x
Free-Float
71.97%
Yield 2026 *
1.85%
Yield 2027 * 1.85%
1 day-1.27%
1 week-3.15%
Current month-2.17%
1 month+0.42%
3 months+12.70%
6 months+28.02%
Current year+47.93%
1 week 56.36
Extreme 56.36
59.63
1 month 54.95
Extreme 54.95
60.44
Current year 38.29
Extreme 38.29
60.44
1 year 34.08
Extreme 34.0805
60.44
3 years 24.05
Extreme 24.05
60.44
5 years 24.05
Extreme 24.05
60.44
10 years 24.05
Extreme 24.05
60.44
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Executive/Senior Manager

-9,099 0.0021%
6/30/26 Sell

Executive/Senior Manager

-130,000 0.0293%
6/30/26 Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-3.15%+53.99%+85.46% 25.6B
+1.73%+2.97%+59.34%+161.90% 1,043B
-0.58%+0.50%+50.71%+48.53% 621B
-0.89%-4.99%+24.58%+62.68% 435B
0.00%+3.20%+46.70%+37.70% 361B
+0.58%-1.26%+35.52%+39.32% 293B
-1.55%-6.84%+7.20%+8.86% 251B
-0.91%+4.33%+42.06%+59.88% 220B
-0.24%-11.27%+1.42%-46.20% 201B
-0.83%-0.02%+19.02%+62.71% 164B
Average -0.34%-3.67%+34.05%+52.08% 361.47B
Weighted average by Cap. +0.16%-3.78%+40.72%+74.69%

Financials

2026 *2027 *
Net sales 3.47B 3.01B 2.82B 2.58B 4.87B 331B 4.94B 33.02B 12.96B 165B 13.04B 12.76B 550B 3.75B 3.26B 3.05B 2.79B 5.27B 358B 5.34B 35.68B 14B 179B 14.09B 13.78B 595B
Net income 1.47B 1.28B 1.19B 1.09B 2.06B 140B 2.09B 13.97B 5.48B 69.96B 5.52B 5.4B 233B 2.16B 1.87B 1.75B 1.6B 3.03B 205B 3.07B 20.5B 8.05B 103B 8.1B 7.92B 342B
Net Debt 9.09B 7.89B 7.39B 6.76B 12.75B 866B 12.92B 86.4B 33.91B 433B 34.13B 33.38B 1,440B 9.27B 8.04B 7.53B 6.89B 13.01B 883B 13.18B 88.13B 34.59B 441B 34.81B 34.05B 1,469B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-08-06 US$57.16 -1.02% 1,289,489
26-08-05 US$57.75 +0.47% 3,536,502
26-08-04 US$57.48 +0.54% 3,684,203
26-08-03 US$57.17 -2.16% 2,747,780
26-07-31 US$58.43 -1.00% 2,156,928
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
57.75USD
Average target price
62.38USD
Spread / Average Target
+8.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock